Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.374
Peer-review started: January 20, 2015
First decision: February 7, 2015
Revised: April 2, 2015
Accepted: April 27, 2015
Article in press: April 29, 2015
Published online: July 6, 2015
Processing time: 167 Days and 15.8 Hours
Patients with renal failure are at increased risk of cardiovascular events even at the earliest stages of disease. In addition to many classic cardiovascular risk factors, many conditions that are commonly identified as emerging risk factors might contribute to occurrence of cardiovascular disease. Changes in circulating levels of many of these emerging risk factors have been demonstrated in patients with early stages of renal failure caused by different types of renal disease and have been associated with detection of cardiovascular complications. However, for most of these factors evidence of benefits of correction on cardiovascular outcome is missing. In this article, we comment on the role of lipoprotein(a) and prothrombotic factors as potential contributors to cardiovascular events in patients with early renal failure.
Core tip: Cardiovascular disease is the leading cause of morbidity and mortality in patients with chronic renal failure and even patients with moderate impairment of renal function have an increased risk to develop cardiovascular events. Traditional cardiovascular risk factors have a leading role in the pathophysiology of accelerated atherosclerosis of patients with renal failure, but emerging non-traditional factors might also be involved. Evidence of a possible contribution of lipoprotein(a) and prothrombotic state to cardiovascular outcomes of patients with early renal failure is discussed in this editorial.
